rDEN2Δ30-7169

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Mahidol University

Conditions

DengueImmune-related Adverse EventSafety IssuesViremia

Early Phase 1

Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.

Not yet recruitingNCT05476757

Mahidol UniversityDengue

Start: 2022-08-31End: 2026-03-31Target: 5Updated: 2022-07-27

Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)

Not yet recruitingNCT06908018

Mahidol UniversityDengue, Immune-related Adverse Event, Safety Issues +1

Start: 2025-09-30End: 2028-09-30Target: 12Updated: 2025-04-03

Phase 1

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

CompletedNCT02392325

National Institute of Allergy and Infectious Diseases (NIAID)Dengue

Start: 2015-03-31End: 2017-02-28Target: 12Updated: 2018-02-08